Incannex Healthcare Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended December 31, 2023 (fiscal Q2 and first half of fiscal 2024). The company is an early-stage drug-development business with no significant product revenue. Financial amounts below are in U.S. dollars; statement amounts are generally in thousands.
Financial performance and position
| Metric | Three months ended Dec. 31, 2023 | Six months ended Dec. 31, 2023 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $2.638 million | $5.247 million |
| General and administrative expense | $5.345 million | $7.629 million |
| Total operating expenses | $7.983 million | $12.876 million |
| R&D tax incentive income | $2.727 million | $6.824 million |
| Net loss | $5.241 million | $5.968 million |
| Operating cash used | Not separately presented | $7.852 million |
At December 31, 2023, cash and cash equivalents were $14.554 million, total current assets $21.332 million, current liabilities $3.186 million, and working capital approximately $18.146 million. Total liabilities were $3.487 million, including operating lease liabilities; the filing reports no borrowings or credit facilities. Cash-flow statement ending cash is $14.555 million, a $1,000 difference from the balance sheet.
There is no meaningful product-revenue margin to assess. For the six months, operating cash use was $7.852 million, investing cash use $0.280 million, and financing cash flow nil. Cash declined by $8.132 million, partly offset by $0.567 million of favorable exchange-rate effects. The company reported $3.471 million of share-based compensation for the period.
Changes versus the prior comparable period
- Quarterly R&D expense rose 71% to $2.638 million; six-month R&D expense rose 77% to $5.247 million, reflecting clinical research and product development, including trials for IHL-42X and IHL-675A.
- Quarterly G&A expense rose 156% to $5.345 million and six-month G&A rose 117% to $7.629 million. The company attributed much of the increase to compensation, including restricted stock issued to directors, and higher legal, compliance and regulatory costs, including costs of re-domiciliation.
- Six-month net loss narrowed from $41.066 million to $5.968 million, primarily because the prior-year period included $35.347 million of acquired in-process R&D expense related to APIRx. The current period’s higher R&D and G&A were partly offset by increased R&D tax incentive income.
- Cash used in operations increased from $5.437 million to $7.852 million. The filing cites a $5.883 million increase in prepaid expenses and other current assets. No financing proceeds were received in the current six-month period, versus $8.280 million in the prior-year period.
- The company completed its re-domiciliation from Australia to Delaware on November 28, 2023, and adopted U.S. GAAP retrospectively for periods presented. Share counts were adjusted for the 100:1 exchange ratio.
Outlook, commentary and risks
Management said cash on hand was expected to fund operations at least until December 2024, while cautioning that this estimate is subject to uncertainty. It expects substantial additional funding will be needed to advance development, anticipates continued losses, and does not expect significant revenue before regulatory approval and product sales. It states that it has no ready access to credit facilities.
A notable estimate change increased the R&D tax incentive receivable and other income by approximately $5 million, following multiple years of incentives being granted and successful lodgement of overseas findings. The balance sheet reported a $5.337 million R&D tax credit receivable. The timing and collectability of this receivable are relevant to liquidity.
Key risks include obtaining additional financing; clinical and regulatory outcomes; commercialization, market acceptance and reimbursement; reliance on third-party research and manufacturing providers; intellectual-property protection; competition; and retaining employees. The company reported no legal or arbitration proceedings expected to have a material adverse effect. Management concluded disclosure controls were effective at period-end and reported no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Confirm the timing, eligibility and cash collection of the $5.337 million R&D tax incentive receivable and assess the effect of the approximately $5 million estimate change.
- Assess cash runway against clinical-trial spending, prepaid costs and management’s stated expectation of funding operations through at least December 2024.
- Review trial progress, costs and regulatory milestones for IHL-42X and IHL-675A, and the company’s plans and capacity to raise additional capital.
- Reconcile the filing’s quarterly 2022 net loss of $2.918 million with the displayed positive $0.05 basic and diluted loss-per-share figure; the filing text does not make this apparent inconsistency clear.
- Check the reported cash balance difference ($14.554 million on the balance sheet versus $14.555 million in the cash-flow statement) and understand dilution from restricted stock, warrants and other share equivalents.